CARLSBAD, CA, USA I December 19, 2016 I Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has advanced its lead drug candidate IONIS-AZ4-2.5-LRx, which has now been renamed AZD8233, into preclinical development. AZD8233 is designed to inhibit an undisclosed target to treat cardiovascular disease and is also the first of a new class of antisense drugs that uses both Ionis’ proprietary Generation 2.5 chemistry and its LIgand Conjugated Antisense or LICA technology. In conjunction with this milestone, Ionis earned a $25 million milestone payment from AstraZeneca (NYSE:AZN).
“This is the first drug to enter development under our strategic collaboration with AstraZeneca in cardiovascular, metabolic and renal diseases. We are pleased with how quickly this important program has advanced. AZD8233 incorporates many of the recent advancements we have made in antisense technology, including LICA and Generation 2.5 chemistry,” said Brett Monia, Ph.D., senior vice president of drug discovery at Ionis. “By combining Generation 2.5 and LICA, we have generated a drug that has the advantages of both higher affinity chemistry and efficient cell-specific targeting. This combination has allowed us to produce a drug that is substantially more potent than either Generation 2.5 or LICA alone, which should support both a very low dose and infrequent dosing.”
As AZD8233 advances in development, Ionis will be eligible to receive up to $300 million in additional development and regulatory milestone payments as well as tiered, low double-digit royalties from sales of the drug. AstraZeneca will be responsible for further developing and commercializing AZD8233.
ABOUT IONIS AND ASTRAZENECA
AstraZeneca and Ionis have a strategic alliance focused on leveraging antisense technology to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The collaboration builds on a broad existing relationship between the two companies and is supported by Ionis’ expertise in cardiovascular disease and antisense technology and AstraZeneca’s drug development expertise and infrastructure. In the collaboration, Ionis is primarily responsible for creating development candidates. AstraZeneca paid Ionis an upfront fee of $65 million at the initiation of the collaboration. Beyond AZD8233, AstraZeneca has the option to license additional antisense drugs upon development candidate nomination and will pay a license fee for each drug licensed plus development and regulatory milestones and sales royalties for each program that AstraZeneca advances. Ionis and AstraZeneca are also collaborating to discover and develop antisense drugs to treat cancer.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with TTR amyloidosis; and SPINRAZATM (nusinersen), a drug licensed by Biogen to treat infantile and later-onset spinal muscular atrophy. Ionis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
ABOUT ASTRAZENECA
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com.
SOURCE: Ionis Pharmaceuticals
